There were no previously known neurological or autoimmune diseases in the patient’s family.ĬCPD is a rare neurological condition which includes heterogeneous clinical presentations such as myeloradiculoneuropathy, encephalopathy, cranial neuropathy, length-dependent peripheral neuropathy or pseudo-Guillain–Barré syndrome and can present in acute, relapsing–remitting and chronic forms. There were no recent travels to foreign countries, introduction of new medication or exposure to toxics. Five days later, he developed bilateral lower limb numbness, gait instability, band-like pain at mid-thoracic level and urinary dysfunction, that progressed over 3 weeks. Twelve weeks after the first administration, the patient received the second dose of AstraZeneca®-ChAdOx1 vaccine. Most complaints remitted spontaneously in 5 days, except for lower limb weakness.
A COVID-19 infection was excluded by two negative SARS-CoV-2 RT-PCR tests. A 48-year-old man with previous essential arterial hypertension medicated with irbesartan, hydrochlorothiazide and lercanidipine, developed anosmia, ageusia, lower limb weakness (noticed by the patient as an increased difficulty to perform his daily exercise routine), and an irregular bowel pattern, 3 weeks after administration of COVID-19 vaccine (AstraZeneca ®- ChAdOx1).
0 kommentar(er)
